Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability